Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director Share Transfer

23rd Dec 2010 07:00

RNS Number : 4877Y
ABCAM Plc
23 December 2010
 



For immediate release

23 December 2010

ABCAM PLC

("Abcam" or "the Company")

Director Share Transfer

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, was notified on 22 December 2010 that, on the same day, a charitable trust of which Jonathan Milner, a Director of the Company, is a Trustee transferred 190,000 ordinary shares of 0.2 pence each in the Company ("Ordinary Shares") to The Chancellor, Masters and Scholars of the University of Cambridge for nil consideration.

Following this transaction, Dr Milner's total beneficial interest in the Company remains unchanged.

 

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Jessica Fontaine

 

 

 

 

 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 68,000 products, most of which are antibodies, from over 250 suppliers and employs 270 staff.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSKKBDKKBDBQBB

Related Shares:

ABC.L
FTSE 100 Latest
Value8,850.63
Change-34.29